Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73607314" target="_blank" >RIV/61989592:15110/21:73607314 - isvavai.cz</a>
Result on the web
<a href="https://nn.neurology.org/content/nnn/8/1/e919.full.pdf" target="_blank" >https://nn.neurology.org/content/nnn/8/1/e919.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/NXI.0000000000000919" target="_blank" >10.1212/NXI.0000000000000919</a>

Result language
angličtina
Original language name
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
Original language description
Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell-related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced stages of clinical development. Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclonal antibody B cell-depleting strategies in NMOSD and the emerging related myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G-associated disease (MOGAD). Case series and phase 2/3 studies in these inflammatory disorders are assessed. The safety profile of long-term B-cell depletion in MS, NMOSD, and MOGAD will be highlighted. Finally implications of the current coronavirus disease 2019 pandemic on the management of patients with these disorders and the use of B cell-depleting agents will be discussed
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)